Trial Profile

A Phase 1/2 Dose-Escalation and Randomized, Controlled, Masked Expansion Trial of Intravitreal 4D-150 Gene Therapy in Adults With Neovascular (Wet) Age-Related Macular Degeneration

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 17 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs 4D-150 (Primary) ; Aflibercept
Indications Wet age-related macular degeneration
Focus Adverse reactions
Acronyms PRISM
Sponsors 4D Molecular Therapeutics

Most Recent Events

07 Jan 2026 According to a 4D Molecular Therapeutics media release, 4D-150 PRISM wet AMD 2-year Phase 2b data expected mid-2026.
06 Nov 2025 According to a 4D Molecular Therapeutics media release, data will be presented in detail at an upcoming scientific conference.
06 Nov 2025 Interim results presented in a 4D Molecular Therapeutics media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com